Hundreds of MSU professors, GEU call to remove VP of research Stephen Hsu
By Wendy Guzman,
The State News
| 06. 15. 2020
The accusations tie back to Hsu’s outspoken advocacy for eugenics, or discouraging reproduction from those with genetic defects and disabilities with the intent of improving the quality of the human species.
The Michigan State University Graduate Employees Union and its coalition partners in the STEM community are calling for MSU to remove Senior Vice President for Research and Innovation Stephen Hsu in a Twitter thread denouncing scientific racism, sexism, eugenicist research and conflicts of interest.
As of 9:00 a.m. Monday, a general petition has about 370 signatures and a separate petition of Michigan State professors has about 300 signatures.
Hsu was hired to lead the university's research enterprise, administering faculty and student research across the university as the Vice President for Research and Graduate Studies under ex-MSU President Lou Anna K. Simon in 2012.
Scientific racism and sexism
Scientific racism is the belief that pseudoscientific evidence can support or justify racism, racial inferiority or racial superiority. The GEU compared Hsu's views to white supremacist Stefan Molyneux, including clips from a podcast between Hsu and Molyneux to support these claims.
"A video from a 2017 podcast interview with Senior Vice President for Research and Innovation Stephen Hsu has offended many people," MSU President Samuel L. Stanley said in a statement. "Regardless...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
